IRD

Opus Genetics, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-12

Figures on this page computed 2026-11-08 12:40 UTC

Last close

4.27USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-03-12

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001140361-26-009247
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-12
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001140361-26-009247
Reported in
USD
- 10-K for 2025, filed 2026-03-12
- 10-K for 2025, filed 2026-03-12
- 10-K for 2025, filed 2026-03-12
- 10-Q for 2025, filed 2026-08-06
- 10-K for 2025, filed 2026-03-12
- 10-Q for 2025, filed 2026-08-06
The filing itself
-349.3%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001140361-26-009247
Reported in
USD
- 10-K for 2025, filed 2026-03-12
- 10-K for 2025, filed 2026-03-12
The filing itself
n/aFCF margin
We do not hold this figure for this company, so there is nothing to place.
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001140361-26-009247
Reported in
USD
- 10-K for 2025, filed 2026-03-12
- 10-K for 2025, filed 2026-03-12
- 10-K for 2025, filed 2026-03-12
The filing itself
0.07Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001140361-26-009247
Reported in
USD
- 10-K for 2025, filed 2026-03-12
- 10-Q for 2025, filed 2026-08-06
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Price is the furthest below its sector's middle: 0.06 against 0.38 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

1.13x

2.10x

n/a

4.06x

1.77x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

4 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-12

Sales1.13x
Its own average over 7 years, 12.5M.
Profit2.10x
Its own average over 10 years, -23.6M.
Free cash flown/a
Its own average over 5 years, -11.6M.
Debt4.06x
Its own average over 6 years, 277.8K.
Price1.77x
Its own average over 3 years, 2. Market data, 2026-11-04

Debt is furthest from its own average, at 4.06 times.

Sales is 1.13 times its own 7-year average; Profit is 2.10 times its own 10-year average; Debt is 4.06 times its own 6-year average; Price is 1.77 times its own 3-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-03-12

Sales against its own 7-year average1.13
Source
filed
Statement
income
Fiscal year
2025
Accession
0001140361-26-009247
Reported in
USD
The filing itself
Profit against its own 10-year average2.10
Source
filed
Statement
income
Fiscal year
2025
Accession
0001140361-26-009247
Reported in
USD
The filing itself
Free cash flow against its own 5-year averagen/a
Not held.
Source
filed
Statement
income
Fiscal year
2025
Accession
0001140361-26-009247
Reported in
USD
The filing itself
Debt against its own 6-year average4.06
Source
filed
Statement
income
Fiscal year
2025
Accession
0001140361-26-009247
Reported in
USD
The filing itself
Price against its own 3-year average1.77Market data, 2026-11-04
Source
market
Taken on
2026-11-04
Reported in
USD